MedTrace Logo

Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

NCT00690300 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2010-03-03

No results posted yet for this study

Summary

The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.

Conditions

  • Pancreas Neoplasms

Interventions

DRUG

Docetaxel

75 mg/m2 IV on day 1 of each 22 day cycle

DRUG

Oxaliplatin

80 mg/m2 IV on day 2 of each 22 day cycle

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Thomas Seufferlein, Prof. Dr. · Universitätsklinikum Halle / Klinik für Innere Medizin I

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690300 on ClinicalTrials.gov